ioxaglate
Trade name: Hexabrix
Small moleculeapproved
Approved
Jul 26, 1985
Ioxaglic acid is pharmaceutical drug used as an iodinated contrast medium for X-ray imaging. It has low osmolality, typically resulting in fewer side effects than high-osmolality media. It is manufactured by Guerbet, but marketing in the US has been discontinued. As of 2021, it may still be available in some European countries. — Wikipedia
Clinical trial activity
0 trials · 0 clinical orgs · 1 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Timeline
Indications
Approved for
Mechanism of action
- contrast mediumRadiopaque
contrast medium radiopaque
Approval history
- approvedJul 26, 1985
Chemistry & pharmacology
Loading structure…
SMILES
CNC(=O)c1c(I)c(C(=O)NCC(=O)Nc2c(I)c(C(=O)O)c(I)c(C(=O)NCCO)c2I)c(I)c(N(C)C(C)=O)c1I.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO- Mol. weight
- 1464.1 g/mol
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaIoxaglic acid ↗
- ChEMBLCHEMBL1200743 ↗
- ChEMBLCHEMBL1200508 ↗
Also known as
- hexabrix
- hexabrix
- ioxaglate meglumine
- ioxaglate meglumine
- ioxaglate meglumine
- ioxaglate meglumine; ioxaglate sodium
- ioxaglate sodium
- ioxaglate sodium
- ioxaglate sodium
- mp-302
- mp-302
- mp-302 (mixt. with ioxaglate sodium)
- mp-302 (mixt. with ioxaglate sodium)
- sodium ioxaglate
- sodium ioxaglate